副鼻腔炎治療の世界市場：現状分析・予測 (2022年～2028年)

副鼻腔炎治療に対する需要の高まりは、鼻副鼻腔炎の有病率の世界的な増加に起因すると考えられています。また、新薬のR&Dへの投資が増加していることも市場の著しい成長の要因となっています。さらに、診断薬に対する需要の高まりから、市場規模は予測期間中、5%のCAGRで成長すると予測されています。

当レポートでは、世界の副鼻腔炎治療の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、法規制環境、需給動向、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 イントロダクション

第2章 調査手法・前提因子

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 COVID-19：副鼻腔炎治療市場への影響

第6章 副鼻腔炎治療市場：収益の推移・予測

第7章 市場洞察：疾患別

• 急性副鼻腔炎
• 亜急性副鼻腔炎
• 慢性副鼻腔炎

第8章 市場洞察：治療法別

• 鎮痛剤
• 抗ヒスタミン剤
• コルチコステロイド
• 抗生物質
• 手術

第9章 市場洞察：地域別

• 北米
• 欧州
• アジア太平洋
• その他の地域

第10章 副鼻腔炎治療市場：市場力学

• 市場促進要因
• 市場課題
• 影響分析

第11章 副鼻腔炎治療市場：市場機会

第12章 副鼻腔炎治療市場：市場動向

第13章 需要サイド・供給サイドの分析

第14章 バリューチェーン分析

第15章 競合シナリオ

第16章 企業概要

• Olympus Corporation
• Medtronic
• Stryker
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd
• Sanofi
• Aurobindo Pharma
• Intersect ENT, Inc.
• Smith+Nephew
• Novartis AG

第17章 免責事項

Sinusitis is a medical condition that causes inflammation along the sinus lining, which can cause symptoms like facial pain, sinus headaches, breathing problems, fatigue, tooth pain, and a loss of taste and smell. The growing demand for sinus treatment can be attributed to the increasing prevalence of rhinosinusitis across the globe. For instance, according to the World Allergy Organization 2021, the worldwide prevalence of chronic rhinosinusitis (CRS) ranges from about 8% in China, 8.4% in Korea, 11% in Europe, and 12% in the United States. Furthermore, the increasing investments in the research and development of novel medicines also attributes to the significant growth of the market.

The increasing demand for diagnostics is expected to drive the global sinusitis treatment market at a CAGR of 5%, during the forecast period. Factors such as rapid technological advancement and integration of information technology in healthcare are important factors responsible for the market growth of the sinusitis treatment market.

Based on the disease, the market has been categorized into acute sinusitis, sub-acute sinusitis, and chronic sinusitis. Among them, the chronic sinusitis segment holds a considerable share of the market. The rising incidences of chronic sinusitis along with the rise in air pollution are the important factors contributing to the share of the chronic sinusitis segment. For instance, according to the National Institute of Allergy and Infectious Diseases (NIAID), an estimated 134 million Indians suffer from chronic sinusitis.

Based on the treatment, the market has been categorized into analgesics, antihistamines, corticosteroids, antibiotics, and surgery. Among them, the antibiotics segment holds a considerable share of the market. The increasing prevalence of high effectiveness of the antibodies against them attributes to the significant share of the antibodies in the sinusitis treatment.

For a better understanding of the market adoption of the sinusitis treatment, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America is anticipated to hold a considerable market share during the forecast period. The rising number of sinusitis cases along with the presence of a large geriatric population in the region attributes to the significant share of sinusitis treatment. For instance, according to the University of Michigan Health Michigan Medicines, Chronic sinusitis affects 31 million people in the U.S. and accounts for more than 16 million outpatient visits a year.

Some of the major players operating in the market are Olympus Corporation; Medtronic; Stryker; Cipla Inc.; Dr. Reddy's Laboratories Ltd; Sanofi; Aurobindo Pharma; Intersect ENT, Inc.; Smith+Nephew; and Novartis AG

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Sinusitis Treatment Market
• 2.2. Research Methodology of the Sinusitis Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE SINUSITIS TREATMENT MARKET

6 SINUSITIS TREATMENT MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY DISEASE

• 7.1. Acute Sinusitis
• 7.2. Sub-acute Sinusitis
• 7.3. Chronic Sinusitis

8 MARKET INSIGHTS BY TREATMENT

• 8.1. Analgesics
• 8.2. Antihistamines
• 8.3. Corticosteroids
• 8.4. Antibiotics
• 8.5. Surgery

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 SINUSITIS TREATMENT MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 SINUSITIS TREATMENT MARKET OPPORTUNITIES

12 SINUSITIS TREATMENT MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Olympus Corporation
• 16.2. Medtronic
• 16.3. Stryker
• 16.4. Cipla Inc.
• 16.5. Dr. Reddy's Laboratories Ltd
• 16.6. Sanofi
• 16.7. Aurobindo Pharma
• 16.8. Intersect ENT, Inc.
• 16.9. Smith+Nephew
• 16.10. Novartis AG

17 DISCLAIMER